NBY Share Price

Open 3.60 Change Price %
High 3.60 1 Day -0.15 -4.11
Low 3.50 1 Week -0.20 -5.41
Close 3.50 1 Month 0.00 0.00
Volume 10024 1 Year 0.30 9.38
52 Week High 5.29
52 Week Low 1.77
NBY Important Levels
Resistance 2 3.59
Resistance 1 3.55
Pivot 3.53
Support 1 3.45
Support 2 3.41
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
NAK 2.96 12.55%
NAK 2.96 12.55%
RBY 0.03 -70.00%
NGD 4.31 2.86%
NGD 4.31 2.86%
PBTH 8.23 0.37%
BTI 118.92 1.38%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
CMFO 0.06 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
More..

NovaBay Pharmaceuticals, Inc. (AMEX: NBY)

NBY Technical Analysis 2
As on 23rd Jan 2017 NBY Share Price closed @ 3.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.05 & Strong Sell for SHORT-TERM with Stoploss of 3.88 we also expect STOCK to react on Following IMPORTANT LEVELS.
NBY Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
NBY Other Details
Segment EQ
Market Capital 38494876.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.novabaypharma.com
NBY Address
NBY
5980 Horton Street
Suite 550
Emeryville, CA 94608
United States
Phone: 510-899-8800
Fax: 510-225-0371
NBY Latest News
Signal Watch: Checking the Numbers for NovaBay Pharmaceuticals Inc. (NBY)   Sherwood Daily   - 24th Jan 17
The NovaBay Pharma (NBY) Short Interest Down 3.0% in December   DailyQuint   - 23rd Jan 17
NovaBay Pharma's (NBY) Hold Rating Reaffirmed at Maxim Group   Sports Perspectives   - 20th Jan 17
NovaBay Pharmaceuticals Announces Preliminary Sales for the Fourth Quarter of 2016   Yahoo Finance   - 09th Jan 17
NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results   Business Wire (press release)   - 11th Nov 16
Where Does NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) Have Its Focus This Year?   Scibility Media   - 15th Aug 16
NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results   Business Wire (press release)   - 12th Aug 16
NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova ...   Business Wire (press release)   - 19th Nov 15
News NovaBay Pharmaceuticals Inc.NBY   Wall Street Journal   - 11th Feb 11
NovaBay Pharmaceuticals Inc.   MarketWatch   - 16th Jul 10
Interactive Technical Analysis Chart NovaBay Pharmaceuticals, Inc. ( NBY AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on NovaBay Pharmaceuticals, Inc.
NBY Business Profile
NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It offers Aganocide compounds, including auriclosene irrigation solution to reduce urinary catheter blockage and encrustation; an eye drop formulation of auriclosene for treating adenoviral conjunctivitis; and a gel formulation of auriclosene for treating impetigo, a highly contagious skin infection. The company also provides NeutroPhase, a skin and wound cleanser for non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.